Disc Medicine, Inc
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
Inclusion Criteria: 1. Aged 18 years or older at the time of signing the informed consent form (ICF). 2. Male or female study participants with SCD HbSC or HbSS. Documentation of SCD genotype may be based on history of laboratory testing or must be confirmed by laboratory testing during Screening. 3. Participants who have been diagnosed with any of the following SCD-related complications: between 1-10 episodes of VOC in the past 12 months, any history of sickle cell related retinopathy, silent cerebral infarct, avascular necrosis, sensorineural hearing loss; or at least 1 episode of priapism,…
DISC-3405 is administered subcutaneously.